Cynthia Rivera, MD
Infectious Disease · Miami Beach, FLNPI 1285835520
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Gilead at 45.0% of the total. Among infectious disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 912 payments — averaging $290.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$119K
- Viiv Healthcare Company$93K
- Aimmune Therapeutics, Inc.$36K
- AbbVie$6K
- Tetraphase Pharmaceuticals, Inc.$3K
- Theratechnologies Inc.$2K
- plus $4K from 19 others
Across 3 payments — averaging $15,402 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Theratechnologies Inc.$46K
What the payments were for
- Consulting fees$93,06535%
- Speaking & faculty fees$126,50348%
- Travel & lodging$25,46510%
- Food & beverage$20,0298%
- Education$3250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 245 | $119,448 |
| Viiv Healthcare Company | 283 | $93,324 |
| Aimmune Therapeutics, Inc. | 40 | $36,163 |
| AbbVie(2 entities) | 134 | $6,182 |
| Tetraphase Pharmaceuticals, Inc. | 11 | $3,466 |
| Theratechnologies Inc. | 16 | $2,374 |
| Johnson & Johnson(2 entities) | 57 | $1,105 |
| Insmed, Inc. | 33 | $705 |
| Merck | 32 | $677 |
| Exeltis, USA Inc. | 1 | $400 |
| Paratek Pharmaceuticals, Inc. | 16 | $357 |
| Janssen Products, LP | 3 | $253 |
| Napo Pharmaceuticals Inc | 11 | $231 |
| Shionogi Inc | 7 | $196 |
| Melinta Therapeutics, LLC | 5 | $117 |
| EMD Serono, Inc. | 5 | $105 |
| La Jolla Pharmaceutical Company | 3 | $73 |
| Sobi, Inc | 1 | $37 |
| Pfizer | 2 | $35 |
| VBI Vaccine (delaware) Inc. | 1 | $28 |
| Cumberland Pharmaceuticals, Inc. | 1 | $27 |
| Astellas Pharma US Inc | 2 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $24 |
| Mayne Pharma Commercial LLC | 1 | $22 |
| Nabriva Therapeutics, PLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$265,387 in reported general payments places this provider in the 95th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 351 | $1,471,243 |
| DovatoDolutegravir Sodium/Lamivudine | 183 | $559,398 |
| SerostimSomatropin | 12 | $251,588 |
| CabenuvaCabotegravir/Rilpivirine | 18 | $122,413 |
| RukobiaFostemsavir Tromethamine | 13 | $114,787 |
| TivicayDolutegravir Sodium | 42 | $106,913 |
| JulucaDolutegravir/Rilpivirine | 20 | $90,226 |
| Egrifta SvTesamorelin Acetate | 11 | $80,959 |
| DescovyEmtricitabine/Tenofov Alafenam | 26 | $59,649 |
| PrezcobixDarunavir/Cobicistat | 12 | $34,273 |
| Maraviroc | 13 | $17,629 |
| ValacyclovirValacyclovir Hcl | 36 | $1,040 |
| Methenamine Hippurate | 13 | $924 |
| Testosterone | 12 | $901 |
| Doxycycline Hyclate | 36 | $489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $119,448 | $1,530,893377 claims |
| Viiv Healthcare CompanyDovato, Cabenuva, Rukobia, Tivicay, Juluca | $93,324 | $993,737276 claims |
| EMD Serono, Inc.Serostim | $105 | $251,58812 claims |
| Theratechnologies Inc.Egrifta Sv | $2,374 | $80,95911 claims |
| Johnson & JohnsonPrezcobix | $1,105 | $34,27312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Miami Beach
- Claudio TudaMiami Beach$221K
- Nicholas CampsMiami Beach$98K
- Joseph ChanMiami Beach$49K
- Amy WeckerMiami Beach$23K
- Lennox ArchibaldGainesville$2.1M
- Moti RamgopalFort Pierce$1.1M
- Juan DiazAltamonte Springs$980K
- Charlotte-Paige RolleOrlando$619K
- Kenneth AlexanderOrlando$474K
- Douglas BrustMiami$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.